Literature DB >> 8484741

Different N-terminal forms of alpha 2-plasmin inhibitor in human plasma.

K Bangert1, A H Johnsen, U Christensen, S Thorsen.   

Abstract

Mature alpha 2-plasmin inhibitor in human plasma has 12 more N-terminal residues than hitherto anticipated. The first residue is the methionine at position 28, downstream from the N-terminus of the pre-protein. The cDNA sequence predicts that the site cleaved upon formation of the mature inhibitor is a typical signal-peptidase recognition site. The mature inhibitor (464 residues) and the previously reported, and presumably degraded, form with N-terminal asparagine (452 residues), are present in plasma in about equal amounts. They both form a stable complex with plasmin. Recent studies on a recombinant alpha 2-plasmin inhibitor suggest that the 12 additional residues have functional implications [Sumi, Ichikawa, Nakamura, Miura and Aoki (1989) J. Biochem. 106, 703-707].

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8484741      PMCID: PMC1132569          DOI: 10.1042/bj2910623

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  22 in total

1.  Kinetic properties of the primary inhibitor of plasmin from human plasma.

Authors:  U Christensen; I Clemmensen
Journal:  Biochem J       Date:  1977-05-01       Impact factor: 3.857

2.  A new family of serine-type peptidases related to prolyl oligopeptidase.

Authors:  N D Rawlings; L Polgar; A J Barrett
Journal:  Biochem J       Date:  1991-11-01       Impact factor: 3.857

3.  Expression and characterization of pro alpha 2-plasmin inhibitor.

Authors:  Y Sumi; Y Ichikawa; Y Nakamura; O Miura; N Aoki
Journal:  J Biochem       Date:  1989-10       Impact factor: 3.387

4.  Properties of three different molecular forms of the alpha 2 plasmin inhibitor.

Authors:  I Clemmensen; S Thorsen; S Müllertz; L C Petersen
Journal:  Eur J Biochem       Date:  1981-11

5.  Demonstration of two forms of alpha 2-antiplasmin in plasma by modified crossed immunoelectrophoresis.

Authors:  C Kluft; N Los
Journal:  Thromb Res       Date:  1981 Jan 1-15       Impact factor: 3.944

6.  Affinity-chromatographic purification of human alpha 2-antiplasmin.

Authors:  B Wiman
Journal:  Biochem J       Date:  1980-10-01       Impact factor: 3.857

7.  Steady-state kinetics of plasmin- and trypsin-catalysed hydrolysis of a number of tripeptide-p-nitroanilides.

Authors:  U Christensen; H H Ipsen
Journal:  Biochim Biophys Acta       Date:  1979-08-15

8.  Inactivation of human plasma alpha 1-proteinase inhibitor by human PMN leucocyte collagenase.

Authors:  V Knäuper; H Reinke; H Tschesche
Journal:  FEBS Lett       Date:  1990-04-24       Impact factor: 4.124

9.  Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis.

Authors:  Y Sakata; N Aoki
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

10.  Kinetics and physiologic relevance of the inactivation of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, and antithrombin III by matrix metalloproteinases-1 (tissue collagenase), -2 (72-kDa gelatinase/type IV collagenase), and -3 (stromelysin).

Authors:  A E Mast; J J Enghild; H Nagase; K Suzuki; S V Pizzo; G Salvesen
Journal:  J Biol Chem       Date:  1991-08-25       Impact factor: 5.157

View more
  18 in total

Review 1.  Molecular basis of thrombolytic therapy.

Authors:  H R Lijnen; D Collen
Journal:  J Nucl Cardiol       Date:  2000 Jul-Aug       Impact factor: 5.952

2.  Stopped-flow fluorescence kinetics of bovine alpha 2-antiplasmin inhibition of bovine midiplasmin.

Authors:  S Christensen; L Sottrup-Jensen; U Christensen
Journal:  Biochem J       Date:  1995-01-01       Impact factor: 3.857

3.  Noncovalent interaction of alpha(2)-antiplasmin with fibrin(ogen): localization of alpha(2)-antiplasmin-binding sites.

Authors:  Galina Tsurupa; Sergiy Yakovlev; Patrick McKee; Leonid Medved
Journal:  Biochemistry       Date:  2010-09-07       Impact factor: 3.162

4.  Enhancement of fibrinolysis by inhibiting enzymatic cleavage of precursor α2-antiplasmin.

Authors:  K N Lee; K W Jackson; V J Christiansen; E K Dolence; P A McKee
Journal:  J Thromb Haemost       Date:  2011-05       Impact factor: 5.824

5.  The effect of a single nucleotide polymorphism on human alpha 2-antiplasmin activity.

Authors:  Victoria J Christiansen; Kenneth W Jackson; Kyung N Lee; Patrick A McKee
Journal:  Blood       Date:  2007-02-22       Impact factor: 22.113

6.  Evidence that alpha2-antiplasmin becomes covalently ligated to plasma fibrinogen in the circulation: a new role for plasma factor XIII in fibrinolysis regulation.

Authors:  M W Mosesson; K R Siebenlist; I Hernandez; K N Lee; V J Christiansen; P A McKee
Journal:  J Thromb Haemost       Date:  2008-06-16       Impact factor: 5.824

7.  A non-reactive glutamine residue of alpha2-antiplasmin promotes interactions with the factor XIII active site region.

Authors:  D B Cleary; P G Doiphode; T M Sabo; M C Maurer
Journal:  J Thromb Haemost       Date:  2009-08-19       Impact factor: 5.824

8.  Evaluation of Fibrinolytic Inhibitors: Alpha-2-Antiplasmin and Plasminogen Activator Inhibitor 1 in Patients with Obstructive Sleep Apnoea.

Authors:  Maciej Zakrzewski; Ewelina Zakrzewska; Paweł Kiciński; Sylwia Przybylska-Kuć; Andrzej Dybała; Wojciech Myśliński; Jolanta Pastryk; Tomasz Tomaszewski; Jerzy Mosiewicz
Journal:  PLoS One       Date:  2016-11-18       Impact factor: 3.240

9.  Plasma Proteolytic Cascade Activation during Neonatal Cardiopulmonary Bypass Surgery.

Authors:  Susan A Maroney; Julie A Peterson; Wes Zwifelhofer; Nicholas D Martinez; Ke Yan; Rachel S Bercovitz; Ronald K Woods; Alan E Mast
Journal:  Thromb Haemost       Date:  2018-08-07       Impact factor: 5.249

Review 10.  Inhibition of Fibrinolysis by Coagulation Factor XIII.

Authors:  Dingeman C Rijken; Shirley Uitte de Willige
Journal:  Biomed Res Int       Date:  2017-07-06       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.